Midatech Pharma plc
MTPH.L
London Stock Exchange18.00
GBp
+17.05
- -
Midatech Pharma plc
MTPH.L
(London Stock Exchange)
Recent
price
18.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Midatech Pharma plc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies using its proprietary drug delivery platforms. The company's primary products and services include the development and manufacturing of nanoparticle-based drug delivery systems designed to improve the pharmacokinetics and targeted delivery of pharmaceutical compounds; portfolio includes treatments targeting rare diseases and oncology. Midatech offers proprietary platforms such as MIDA Nanomedicine and MidaSolve, aimed at improving drug solubility, stability, and controlled release. The company operates primarily in Europe and North America, focusing on partnerships with pharmaceutical companies to co-develop and license its technologies. Founded in 2001, Midatech Pharma is headquartered in the United Kingdom with additional operations aligned with its research and commercial activities. In the past one to two years, Midatech Pharma has undergone significant strategic changes, including recent fundraising efforts to advance clinical development programs and expand its commercial pipeline. The company has launched new product candidates utilizing its cutting-edge drug delivery platforms and has entered new strategic partnerships to bolster its R&D capabilities and market reach. Midatech has emphasized operational efficiencies and business expansion initiatives to strengthen its position within the specialty pharmaceutical industry. These efforts reflect a major strategic focus on leveraging its nanomedicine expertise to address unmet medical needs in rare diseases and oncology. Midatech Pharma operates within the biotechnology and specialty pharmaceutical sectors, targeting niche therapeutic areas with high unmet medical needs. Its products serve pharmaceutical partners and healthcare providers aiming to enhance treatment efficacy through advanced drug delivery technologies. The company benefits from its proprietary technology platforms that differentiate its offerings and create value in drug formulation and delivery. Midatech's comprehensive approach includes research, development, manufacturing, and licensing activities, supporting its role as a technology innovator and collaborative partner in the global pharmaceutical landscape.